Nanobiotix got the all-clear for its new Phase I/II clinical trial

02/07/2015 - 2 minutes

The French National Agency for Medicines and Health Products gave Nanobiotix the green light to start a Phase I/II trial in two new cancer populations for its lead product, NBTXR3. This could lead to an increase in the commercial potential of this promising French Biotech.

Nanobiotix is a great French Biotech company, which you can discover better in our exclusive interview of its charismatic CEO Laurent Levy.laurent_levy_nanobiotix

This new phase I/II study will evaluate the use of NBTXR3 in hepatocellular cancer and liver metastases. In the clinical trial, the candidate will be activated with high precision radiation therapy, delivered as high dose fractions, known as Stereotatic Body Radiation Therapy.

This type of therapy is the safest and most modern radiotherapy currently available for the treatment of malignant liver tumors, although it has been shown to be efficient only in specific subsets of the population with small tumors.

Liver cancers are challenging diseases to address. Most patients, either with hepatocellular cancer or liver metastases,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member